Analysis on the clinical outcome of intensity-modulated radiotherapy for 38 patients with prostate carcinoma
- Author:
Ying LI
1
Author Information
1. Second Department of Oncology
- Publication Type:Journal Article
- Keywords:
Prognosis;
Prostatic neoplasms;
Radiotherapy, intensity modulated
- From:
Tumor
2007;27(12):990-993
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the clinical outcome, side effects and prognosis of prostate carcinoma patients treated with intensity-modulated radiotherapy (IMRT). Methods: The clinical data from 38 prostate carcinoma patients who had received IMRT were retrospectively analyzed. Thirty seven patients underwent orchiectomy before radiotherapy and 35 patients received orchiectomy combined with hormone treatment. The concentration of PSA was about 23. 5-159. 0 ng/mL (median value = 36.0 ng/mL). Thirty six patients completed the whole procedure of IMRT. All patients received IMRT radiation therapy with a median dose of 68.6 Gy (60-72 Gy/38-50 d), 2.0-3.0 Gy per fraction, 4-5 times every week. Results: The overall 3-year survival rate was 87.6% and 5-year total survival rate was 75.2%. The frequency of grade I and grade II acute rectal toxicity were 30.6% and 8.33%, respectively. The frequencies of grade I and grade II acute bladder toxicity were 38.9% and 5.56%, respectively. Grade Ill and IV acute toxicity were not observed in rectum and bladder. Conclusion: IMRT can increase the local dosage of radiation in prostate cancer. The rate of toxicity of the surrounding tissues was lower. Patients has higher survival rate and good tolerability. IMRT combined with endocrine therapy does not increase the toxicities of rectum and bladder.
